688319.SH
Chengdu Olymvax Biopharmaceuticals, Inc.
SSE · Healthcare · Biotechnology · CN
CNY 27.82
−7.42%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenCNY 27.12
From 52W high−37.31%
Volume6.58M
Market capCNY 11.28B
P/E (TTM)506.7x
P/S (TTM)14.5x
Div yield—
Key dataSep 18, 2026
Open
CNY 27.12
From 52W high
−37.31%
Volume
6.58M
Market cap
CNY 11.28B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
163.2x
P/E (TTM)
506.7x
RSI (14)
48.6
MomentumView details →
1D Return
−7.42%
YTD Return
—
Similar companies
Latest newsMore news →
On August 31, 2026, ten A-share listed companies including Olymvax Biopharmaceuticals, Xiaocheng Technology, Hengyin Technology, Xinhongye, Feirongda, Ruison Technology, Weiteng Electric, Jinge New Materials, Baling Oriental, and Bestore disclosed plans to reduce their holdings, while ST Kaili and XCMG disclosed plans to increase holdings.20d agoOlymvax Biopharmaceuticals director and deputy general manager Chen Aimin plans to reduce his shareholding in the company by up to 0.0338% of total shares.20d agoOlymvax Biopharmaceuticals reported a net loss of 32.8726 million yuan for the first half of 2026, turning from a profit of 13.1969 million yuan a year earlier, with revenue of 361 million yuan, up 18.14% year-on-year.34d ago